At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Efzofitimod 1 mg/kg +2 moredrug
Likely dose
Efzofitimod 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)
In Brief
A Phase 2 clinical trial evaluating Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, and 1 other intervention for SARS-CoV-2 (COVID-19) Severe Pneumonia. Completed, enrolled 36 participants across 10 sites in 2 countries.
Detailed Summary
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 (COVID-19) Severe Pneumonia
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJun 2020
Primary CompletionOct 2020
TodayJul 2026
First PostedJun 2, 2020
Enrollment StartJun 4, 2020
Primary CompletionOct 23, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.1 years ago
Interventions
Efzofitimod 1 mg/kgdrug
Concentrate for solution for infusion
Efzofitimod 3 mg/kgdrug
Concentrate for solution for infusion
Placebodrug
Concentrate for solution for infusion